I posted this on the Noxopharm board, but it is equally relevant here.
Do I detect a modest uptick in the SP (of NOX)? I wonder whether the buyers expect the SP to increase on Thursday, when Nyrada lists?
Nyrada has developed an oral PCSK9 inhibitor, much to the chagrin of Big Pharma - who tried, and failed. It also has a drug that is expected to alleviate the effects of stroke and concussion and sound damage. My guess is that these drugs will be of great interest to other companies, but I hope that Nyrada plays hard-to-get. However it pans out, the future looks promising for Nyrada AND for Noxopharm, who will hold 40% of NYR, fully diluted.
The worm turns?
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.004(7.02%) |
Mkt cap ! $9.657M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.6¢ | 5.3¢ | $4.061K | 75.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 140989 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 177449 | 3 |
View Market Depth
| Last trade - 15.54pm 26/07/2024 (20 minute delay) ? |
| NYR (ASX) Chart |